Quick Answer
STANDARD BIOTOOLS INC. reported Total Revenue of $85.33 million for fiscal year 2025.
STANDARD BIOTOOLS INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $85.33M -6.2% |
$91.01M -14.4% |
$106.34M +8.6% |
$97.95M -25.0% |
$130.58M -5.5% |
$138.14M +17.8% |
| Revenue (ASC 606) | $85.33M -6.2% |
$91.01M -14.4% |
$106.34M +8.6% |
$97.95M -25.0% |
$130.58M -5.5% |
$138.14M +17.8% |
| Net Income | -$74.90M +46.1% |
-$138.88M -86.0% |
-$74.66M +60.7% |
-$190.10M -220.9% |
-$59.24M -11.7% |
-$53.02M +18.2% |
| Diluted EPS | -$0.20 +61.5% |
-$0.52 +44.7% |
-$0.94 +61.3% |
-$2.43 -211.5% |
-$0.78 -5.4% |
-$0.74 +23.7% |
| Total Assets | $567.75M -7.3% |
$612.35M +89.5% |
$323.07M -17.2% |
$390.31M +41.8% |
$275.21M -15.3% |
$324.76M +22.6% |
| Cash and Equivalents | $120.86M -27.5% |
$166.73M +222.5% |
$51.70M -36.4% |
$81.31M +185.8% |
$28.45M -58.5% |
$68.52M +216.3% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $424.29M -10.1% |
$471.72M +418.6% |
-$148.05M -81.7% |
-$81.47M -186.1% |
$94.60M -32.0% |
$139.05M -9.5% |
| R&D Expense | $25.99M -9.9% |
$28.83M +11.1% |
$25.95M -30.6% |
$37.38M -1.5% |
$37.94M +4.1% |
$36.46M +15.2% |
| Operating Income | -$110.25M +13.5% |
-$127.48M -66.4% |
-$76.60M +34.1% |
-$116.20M -72.3% |
-$67.46M -32.2% |
-$51.04M +1.5% |
| Gross Profit | $42.54M -5.2% |
$44.88M -11.0% |
$50.45M +36.2% |
$37.05M | — | — |
| Shares Outstanding | 386.38M +2.3% |
377.53M +370.5% |
80.23M +0.9% |
79.48M +3.3% |
76.92M +3.2% |
74.54M +6.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $19.55M | -11.5% | -10.2% |
| Revenue (ASC 606) | September 30, 2025 | $19.55M | -11.5% | -10.2% |
| Net Income | September 30, 2025 | -$34.69M | -28.8% | -3.7% |
| Diluted EPS | September 30, 2025 | -$0.09 | -28.6% | +0.0% |
| Total Assets | September 30, 2025 | $539.64M | -20.8% | -3.1% |
| Cash and Equivalents | September 30, 2025 | $129.42M | -38.6% | -18.4% |
| Long-Term Debt | September 30, 2012 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $399.66M | -18.3% | -5.9% |
| R&D Expense | September 30, 2025 | $6.36M | -8.4% | +2.2% |
| Operating Income | September 30, 2025 | -$32.94M | -23.4% | -28.2% |
| Gross Profit | September 30, 2025 | $9.48M | -21.8% | -10.8% |
| Shares Outstanding | September 30, 2025 | 383.61M | +3.0% | +0.5% |
- STANDARD BIOTOOLS INC. reported Total Revenue of $85.33 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -6.2% in Total Revenue compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Revenue (ASC 606) of $85.33 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -6.2% in Revenue (ASC 606) compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Net Income of -$74.90 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed an increase of +46.1% in Net Income compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Diluted EPS of $0.20 per share (loss) for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed an increase of +61.5% in Diluted EPS compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Total Assets of $567.75 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -7.3% in Total Assets compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Cash and Equivalents of $120.86 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -27.5% in Cash and Equivalents compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Long-Term Debt of $0.00 for fiscal year 2012.
- STANDARD BIOTOOLS INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Stockholders Equity of $424.29 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -10.1% in Stockholders Equity compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported R&D Expense of $25.99 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -9.9% in R&D Expense compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Operating Income of -$110.25 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed an increase of +13.5% in Operating Income compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Gross Profit of $42.54 million for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -5.2% in Gross Profit compared to the prior fiscal year.
- STANDARD BIOTOOLS INC. reported Shares Outstanding of 386.38 million shares for fiscal year 2025.
- STANDARD BIOTOOLS INC. showed an increase of +2.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: